Conference
Abstract PD1-10: Randomized phase II study comparing two different schedules of palbociclib plus second line endocrine therapy in women with estrogen receptor positive, HER2 negative advanced/metastatic breast cancer: CCTG MA38 (NCT02630693)
Abstract
Abstract
Background: Palbociclib is approved for treatment of ER+, HER2- ABC at a standard dose of 125 mg po daily 3 weeks on/1 week off (STD). We evaluated the efficacy, safety, quality of life (QOL) and compliance of a 100 mg continuous daily dose (CDD) of palbociclib based on modeling data that suggested efficacy and tolerability.
Authors
Parulekar W; Joy A; Gelmon K; Mates M; Desbiens C; Clemons M; Taylor S; Lemieux J; Bartlett J; Whelan T
Volume
79
Publisher
American Association for Cancer Research (AACR)
Publication Date
February 15, 2019
DOI
10.1158/1538-7445.sabcs18-pd1-10
Conference proceedings
Cancer Research
Issue
4_Supplement
ISSN
0008-5472